Figure 1

Figure 1A




Figure 1B




Figure 2

Figure 2A




Figure 2B




Figure 3A



Medium
IgA [10 mg/ml]
Neutrophil death [%]
100
80
60
40
20
0
Medium
GM-CSF
G-CSF
IFN-alpha
IFN-gamma
TNF-alpha
LPS
LTA

Figure 3B



* 0.031
** 0.0052
** 0.0012
Medium
anti-CD89
Neutrophil death [%]
100
80
60
40
20
0
Medium
GM-CSF
G-CSF
IFN-alpha
IFN-gamma
TNF-alpha
LPS
LTA

Figure 3C



Neutrophil death [%]
100
80
60
40
20
0
Medium
GM-CSF
LPS
Medium
GM-CSF
LPS
Monomeric Plasma IgA
Total Plasma IgA

Figure 4



IgG1control
IgG1
anti-CD89 ankylosing spondyloarthritis
anti-CD89 healthy control
Counts
Fluorescence intensity

Figure 5A



Neutrophil death [%]
100
80
60
40
20
0
Medium
Anti - CD89
Controls
Rheumatoid Arthritis
Ankylsoing spondyloarthritis
Psoriatic arthritis
Unknown arthritis

Figure 5B



Neutrophil death [%]
100
80
60
40
20
0
Control
Arthritis
Medium
anti-CD89 [5µg/ml]
IgA [10mg/ml]
Time: 24hours; n=3

Figure 6



Neutrophil death [%]
0
20
40
60
80
100
Medium
GM-CSF
LPS
Plasma IgA [10mg/ml]
Plasma IgA+qVD [20μM]
Anti-Fas
Anti-Fas+qVD [20μM]

Figure 7A




Medium
0
3
42
55
GM-CSF
1
1
66
33
LPS
1
6
43
51
Plasma IgA
1
7
27
65
GM-CSF + Plasma IgA
1
15
14
70
LPS + Plasma IgA
1
14
12
74
Anti-CD89
1
26
16
57
GM-CSF + anti-CD89
1
16
17
66
LPS + anti-CD89
3
77
3
19
Anti-Fas
0
14
12
74
GM-CSF + anti-Fas
0
6
17
77
LPS + anti-Fas
0
8
19
74
Propidium iodide
Phosphatidyl serine

Figure 7B


Medium
37%
Counts
DNA
GM-CSF
6%
Counts
DNA
LPS
34%
Counts
DNA
Plasma IgA
53%
Counts
DNA
GM-CSF + PlasmaIgA
85%
Counts
DNA
LPS + Plasma IgA
48%
Counts
DNA
Anti-CD89
82%
Counts
DNA
GM-CSF + Anti-CD89
89%
Counts
DNA
LPS + anti-CD89
93%
Counts
DNA
Anti-Fas
89%
Counts
DNA
GM-CSF + anti-Fas
82%
Counts
DNA
LPS + anti-Fas
76%
Counts
DNA